Patients exposed to daratumumab showed a trend of being at higher risk of mobilization failure, although not statistically significant in multivariate analysis (OR=2.17, 95% CI: 0.39-12.11; P =0.37; Table 4 ).
← all excerpts
A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
1
—
—